Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Botulinum Toxin Type A (Sf9, 150 kD) for Moderate to Severe Glabellar Lines – Phase II
CTR20260065Phase 2Active
- Sponsor
- Ruoyi Biotech
- Start
- Jan 2026
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in glabellar furrowing, sponsored by Ruoyi Biotech. Started Jan 2026; status: active.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20260065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260065.